Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Erasca, Inc. Market Cap
Based on ratings from 0 stock analysts, the Erasca, Inc. stock price is expected to increase by 58.68% in 12 months. This is calculated by using the average 12-month stock price forecast for Erasca, Inc.. The lowest target is $3 and the highest is $7. Please note analyst price targets are not guaranteed and could be missed completely.
About 0 Wall Street analysts have assignedERAS 0 buy ratings, 0 hold ratings, and 0 sell ratings. This means that analysts expect Erasca, Inc. to sell. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on ERAS. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of ERAS.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Chris Shibutani Goldman Sachs | Buy | $3 | Maintains | Aug 14, 2024 |
| Andres Maldonado HC Wainwright & Co. | Buy | $6 | Maintains | Aug 13, 2024 |
| Chris Shibutani Goldman Sachs | Buy | $4 | Maintains | May 28, 2024 |
| Andres Maldonado HC Wainwright & Co. | Buy | $5 | Maintains | May 20, 2024 |
| Andres Maldonado HC Wainwright & Co. | Buy | $8 | Reiterates | May 9, 2024 |
| Chris Shibutani Goldman Sachs | Buy | $7 | Maintains | Apr 2, 2024 |
| Andres Maldonado HC Wainwright & Co. | Buy | $8 | Reiterates | Mar 28, 2024 |
| Naureen Quibria Capital One | Overweight | $8 | Initiates | Mar 11, 2024 |
| Alec Stranahan B of A Securities | Neutral | $6 | Downgrade | Jan 5, 2024 |
| Mara Goldstein Mizuho | Buy | $7 | Maintains | Nov 29, 2023 |
| Andres Maldonado HC Wainwright & Co. | Buy | $8 | Maintains | Nov 28, 2023 |
| Andres Maldonado HC Wainwright & Co. | Buy | $10 | Initiates | Oct 11, 2023 |
| Mara Goldstein Mizuho | Buy | $8 | Maintains | Jun 6, 2023 |
| Josh Schimmer Evercore ISI Group | Outperform | $11 | Maintains | Jun 6, 2023 |
| Chris Shibutani Goldman Sachs | Buy | $9 | Maintains | May 16, 2023 |
| Mara Goldstein Mizuho | Buy | $9 | Initiates | Mar 30, 2023 |
| Chris Shibutani Goldman Sachs | Buy | $10 | Initiates | Feb 24, 2023 |
| Jeffrey Hung Morgan Stanley | Overweight | $15 | Upgrade | Feb 3, 2023 |
| Geoff Meacham B of A Securities | Buy | $28 | Initiates | Aug 10, 2021 |
| Jeffrey Hung Morgan Stanley | Equal-Weight | $25 | Initiates | Aug 10, 2021 |
When did it IPO
2021
Staff Count
126
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Dr. Jonathan E. Lim M.D.
Market Cap
$802.3M
In 2023, ERAS generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that ERAS's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Mon, 11 Dec 2023
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - First-in-class and best-in-class potential in NRAS-mutated melanoma and other RAS/MAPK pathway-altered solid tumors Naporafenib has been dosed in more than 500 patients to date, establishing its safety, tolerability, and preliminary proof-of-concept in multiple indications Pivotal Phase 3 SEACRAFT-2 trial initiation in NRAS-mutated melanoma on track for H1 2024 SAN DIEGO, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that the United States Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to naporafenib in combination with trametinib (MEKINISTu00ae) for the treatment of adult patients with unresectable or metastatic melanoma who have progressed on, or are intolerant to, an antiu2011programmed death-1 (ligand 1) (PDu2011(L)1)-based regimen, and whose tumors contain an NRAS mutation (NRASm). Naporafenib is an orally available, Phase 3-ready pan-RAF inhibitor with a potential first-in-class and best-in-class profile in NRASm melanoma and other RAS/MAPK pathway-altered solid tumors.
Fri, 08 Dec 2023
Sentiment - POSITIVE
Source - PennyStocks
Summary - Penny stocks, defined as stocks trading under $5 per share, are known for their volatility. Even small pieces of news or unconfirmed rumors can send some penny stocks swinging wildly up or down in price.
Thu, 07 Dec 2023
Sentiment - POSITIVE
Source - PennyStocks
Summary - Penny stocks u2013 the cheap stocks trading under $5 per share, offer investors massive upside potential alongside higher risk. Since even incremental price moves translate into huge percentage gains in the stock market, timing entries right can set you up for explosive profits.
Tue, 28 Nov 2023
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Gained alignment with global health authorities for pivotal Phase 3 SEACRAFT-2 trial design for naporafenib plus trametinib in NRAS mutant melanoma; initiation on track for H1 2024
Thu, 09 Nov 2023
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - First patient dosed in SEACRAFT-1 Phase 1b trial evaluating naporafenib plus trametinib Multiple upcoming catalysts across ongoing clinical programs Strong balance sheet with cash, cash equivalents, and marketable securities of $344 million as of September 30, 2023 SAN DIEGO, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today reported financial results for the fiscal quarter ended September 30, 2023, and provided business updates. u201cIn 2023, we have continued to make exciting progress across our pipeline,u201d said Jonathan E.
Wed, 08 Nov 2023
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - SAN DIEGO, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancer, today announced that management will participate in the following investor conferences in November 2023. Management will also participate in one-on-one investor meetings.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
